PD profiling of RO6839921 was therefore conducted on plasma and tumour samples harvested at 3, 6 and 24 h post‐treatment using Western analysis for p53, p21 and MDM2, and MIC‐1 ELISA assays (Fig. 2c–e). The gene discussed is TP53; the disease is neoplasm.